Doxorubicin-induced cardiomyopathy treated with carvedilol

被引：44
|
作者：
Fazio, S [1 ]
Palmieri, EA [1 ]
Ferravante, B [1 ]
Bone, F [1 ]
Biondi, B [1 ]
Sacca, L [1 ]
机构：
[1] Univ Naples Federico II, Div Med Interna 3, Sch Med, Dept Internal Med, I-80131 Naples, Italy
来源：
CLINICAL CARDIOLOGY | 1998年 / 21卷 / 10期
关键词：
doxorubicin; cardiomyopathy; carvedilol;
D O I：
10.1002/clc.4960211017
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Even today, heart failure due to doxorubicin-induced dilated cardiomyopathy seems to have a poor prognosis, as it is often irreversible and relatively unresponsive to standard medical treatment. This paper describes the first case of a patient complaining of severe symptoms of congestive heart failure due to doxorubicin-induced dilated cardiomyopathy unresponsive to standard medical treatment (digoxin, diuretics, and angiotensin-converting enzyme inhibitor), who showed complete clinical recovery and significant improvement of left ventricular dysfunction after carvedilol treatment. It also illustrates the possibility that carvedilol may be a first-choice drug for the treatment of this disease.
引用
收藏
页码：777 / 779
页数：3
相关论文
共 50 条
  • [21] Mitochondrial Determinants of Doxorubicin-Induced Cardiomyopathy
    Wallace, Kendall B.
    Sardao, Vilma A.
    Oliveira, Paulo J.
    CIRCULATION RESEARCH, 2020, 126 (07) : 926 - 941
  • [22] Cardioprotective Effects of Carvedilol in Inhibiting Doxorubicin-induced Cardiotoxicity
    Nabati, Maryam
    Janbabai, Ghasem
    Baghyari, Saideh
    Esmaili, Khadige
    Yazdani, Jamshid
    JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 2017, 69 (05) : 279 - 285
  • [23] Can Dexrazoxane and Carvedilol prevent Doxorubicin-induced nephrotoxicity?
    Szponar, Jaroslaw
    Gorska, Agnieszka
    Ostrowska-Lesko, Marta
    Wielgomas, Bartosz
    Mandziuk, Slawomir
    CURRENT ISSUES IN PHARMACY AND MEDICAL SCIENCES, 2024, 37 (04) : 232 - 239
  • [24] Antioxidant, antiapoptotic, and antifibrotic effects of the combination of liposomal resveratrol and carvedilol against doxorubicin-induced cardiomyopathy in rats
    Alanazi, Abeer
    Fadda, Laila
    Alhusaini, Ahlam
    Ahmad, Rehab
    JOURNAL OF BIOCHEMICAL AND MOLECULAR TOXICOLOGY, 2020, 34 (07)
  • [25] Early Administration of Carvedilol Protected against Doxorubicin-Induced Cardiomyopathy (vol 355, pg 516, 2015)
    Chen, Y. L.
    Chung, S. Y.
    Chai, H. T.
    Chen, C. H.
    Liu, C. F.
    Chen, Y. L.
    Huang, T. H.
    Zhen, Y. Y.
    Sung, P. H.
    Sun, C. K.
    Chua, S.
    Lu, H., I
    Lee, F. Y.
    Sheu, J. J.
    Yip, H. K.
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2017, 360 (02): : 312 - 312
  • [26] Mitochondria and Doxorubicin-Induced Cardiomyopathy: A Complex Interplay
    Schirone, Leonardo
    D'Ambrosio, Luca
    Forte, Maurizio
    Genovese, Riccardo
    Schiavon, Sonia
    Spinosa, Giulia
    Iacovone, Giuliano
    Valenti, Valentina
    Frati, Giacomo
    Sciarretta, Sebastiano
    CELLS, 2022, 11 (13)
  • [27] Heart rate dynamics in doxorubicin-induced cardiomyopathy
    Loncar-Turukalo, T.
    Vasic, M.
    Tasic, T.
    Mijatovic, G.
    Glumac, S.
    Bajic, D.
    Japunzic-Zigon, N.
    PHYSIOLOGICAL MEASUREMENT, 2015, 36 (04) : 727 - 739
  • [28] Naproxen aggravates doxorubicin-induced cardiomyopathy in rats
    Pathan, Rahila Ahmad
    Singh, Bhulan Kumar
    Pillai, K. K.
    Dubey, Kiran
    INDIAN JOURNAL OF PHARMACOLOGY, 2010, 42 (01) : 44 - 49
  • [29] Chemical Chaperone Attenuated Doxorubicin-induced Cardiomyopathy
    Fu, Haiying
    Sanada, Shoji
    Minamino, Tetsuo
    Komuro, Issei
    JOURNAL OF CARDIAC FAILURE, 2012, 18 (10) : S166 - S166
  • [30] Molecular mechanism of doxorubicin-induced cardiomyopathy - An update
    Renu, Kaviyarasi
    Abilash, V. G.
    Pichiah, Tirupathi P. B.
    Arunachalam, Sankarganesh
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2018, 818 : 241 - 253
12345